Francesco Maria Senatore

Report
Il Polo senese ed il Distretto regionale
scienze della vita nella prospettiva
europea
Dr. Francesco Maria Senatore
Business Development
Toscana Life Sciences Foundation
TLS 2013
Argomenti
•
•
•
•
•
TLS 2013
Polo Senese: TLS
Distretto: Cluster Regionale
Il mercato della Salute in Europa
Le necessità delle imprese
Evoluzione del Cluster
www.toscanalifesciences.org
TLS 2013
TLS Mission
MPS
Public Institutions
University
Applied Research
Results
Industrial
Development
Territory
TLS 2013
Siena - The Science Park
 Monothematic : Life Sciences (Red Biotech)
 drugs
 diagnostics
 medical devices
 biomedical technologies
 Laboratories, offices, equipment and utilities
 Consulting services and support
 Access to public and private financing tools
JCVI April 2012
Science Park Location: Siena - Novartis site
Total surface area:
83.000 sq. mt.
Total buildings surface:
38.400 sq. mt.
Labs (research/devel./Q.A.):
8.200 sq. mt.
Production plants:
6.800 sq. mt.
Warehouses:
2.800 sq. mt.
Offices:
8.400 sq. mt.
Services:
4.700 sq. mt.
TLS bio-incubator
 Industrial and academic research activities
Center of excellence for Novartis Vaccines
More than 470 researchers
 Common facilities, services and utilities
JCVI April 2012
TLS Bio-incubator
 10 laboratory modules (ranging from 60 to 140 m2) fully
equipped according to company’s needs
 GMP facility for medicinal products derived from human blood
or plasma (160 m2)
 Analytical labs and common services (135 m2)
 BSL 3 lab
 Animal care facility
 Offices, meeting rooms (600 m2)
JCVI April 2012
TLS - Main Incubation Services
 Intellectual property protection consultancy
 Technology Transfer/Start-up Creation
 Business development coaching
 Grants search and application support
 Scouting of industrial and financial partners
 Bio-partnering support
 Infrastructure Services (Front office, meeting room, etc.)
 Dedicated scientific equipment up to € 200k
 Common high-tech equipment and facilities
JCVI April 2012
Incubation Deal-Flow: the ”Picking the Winner
Approach”
International Call for Application
Business Plan submission
Project selection
TLS Executive Board approval
Find Start up financing
Incubation
JCVI April 2012
TLS Evaluation Committee
Dr. Andy Richards, Cambridge (UK)
Prof. Stephen Hanessian, Montréal (CA)
Dr. Elkan Gamzu,
Boston (USA)
JCVI April 2012
Dr. Bertil Samuelsson, Stockholm (SE)
Dr. Eva Pisa, Stockholm (SE)
Torre Fiorentina Campus – September 2005
JCVI April 2012
Companies and Research Groups 2013
TLS 2013
TLS Performance Indicators
2007
2010
2011
2012
10
-
70
93
112
15
48
63
Patent Applications
8
25
22
24
Granted Patents
5
24
25
27
Collab./Agreem./Licensing
34
48
66
Diagnostics Prototypes
8
-
6
8
23
Compounds in Clinical Phases
-
1
-
2
Products on the Market
1
-
12M
25M
32.7 M
22
44.0 M
-
-
1.5 M
3.1 M
Employees
Scientific Publications
Investments Attraction
Companies Revenue
TLS 2013
TLS Incubated Companies & Research Groups:
Total Financial Resources
Companies and Research Groups Financial Resources (2011)
Stakeholders Investment
Local Seed Funds
Regional Seed Funds
Other Funds
Grants
TOTAL
JCVI April 2012
Companies
17.879.159
6.280.000
2.350.000
2.350.000
8.609.809
37.468.967
%
47,7
16,7
6,3
6,3
23
100
Companies & Research Group
18.689.159
6.280.000
2.350.000
2.350.000
14.354.409
44.023.567
%
42,5
14,3
5,3
5,3
32,6
100
TLS 2013
Universities and Research Centers
JCVI April 2012
Tuscany -Health Care System Quality
“33,9% of total clinical trials carried out in Italy are performed in
Tuscany”
JCVI April 2012
Some Big Players
TLS 2013
Tuscany is a strategic region in the Life Science
Companies
Tuscany
% Tuscany
Biotech
221
30
14
Pharma
198
20
10
2.735
156
6
Medical Devices
Turnover ( € Mil .)
Biotech
Italy
Tuscany
% Tuscany
7.157
1.630
23
Pharma
25.000
3.300
13
Medical devices
16.800
811
5
10.940
645
6
Pharma Services
TLS 2013
Italy






TLS 2013
Affiliated Companies
Employees
R&D Employees
Turnover in € Mil.
Labs square meters
Patents
104
10.646
1.376
5.233
31.203
775
The Tuscany Life Science Cluster
National
&
international
clusters
Public
Institutions
Tuscany Life Sciences Cluster
Steering
Committee
Member
Representatives
Committee
Services
Needs
Entrepreneurial
System
TLS 2013
EU Healthcare Market
Organisation for Economic Cooperation and Development
(OECD)
www.oecd.org/
TLS 2013
TLS 2013
•Growth in health spending per capita slowed or fell in real terms in
2010 in almost all European countries, reversing a trend of steady
increases.
•Spending had already started to fall in 2009 in countries hardest
hit by the economic crisis but this was followed by deeper cuts in
2010 in response to growing budgetary pressures and rising debtto-GDP ratios.
•On average across the EU, health spending per capita increased
by 4.6% per year in real terms between 2000 and 2009, followed
by a fall of 0.6% in 2010.
TLS 2013
TLS 2013
•Reductions in public spending on health were
achieved through a range of measures, including
reductions in wages and/or employment levels,
increasing direct payments by households for certain
services and pharmaceuticals, and imposing severe
budget constraints on hospitals.
•Gains in efficiency have also been pursued through
mergers of hospitals or accelerating the move from
inpatient care to outpatient care and day surgery.
TLS 2013
•The public sector is the main source of health care
financing in all European countries.
•In 2010, nearly three-quarter (73%) of all health
spending was publicly financed on average in EU
member states.
•Public financing accounted for over 80% in the
Netherlands, the Nordic countries (except Finland),
Luxembourg, the
TLS 2013
Service support to Life Science
SME
TLS 2013
Internazionalization is a challenge
for SMEs
TLS 2013
SME’s support need for foreign markets
• Align your product portfolio to the markets with high growth
potential (market Analysis)
• Develop market-entry and market-expansion strategies by
identifying the regions and market segments poised for strong
growth (Strategic Positioning)
• Create a more tailored country strategy through the
understanding of market outlook and major trends (local link)
• Develop key strategic initiatives by understanding the key
focus areas and top-selling products of leading companies
(match making events)
TLS 2013
Internationalization
support
Deep insight into
companies’ needs
Framework agreements
with institutional partners
Network of selected and
qualified partners
Networking Europe’s Biocommunities
TLS 2013
ALISEI, Cluster nazionale
Scienze della Vita
“Advanced LIfe SciEnces in Italy”
National Technology Cluster Call
•
•
•
a)
b)
c)
d)
•
The MIUR (Ministry of Education, Universities and Research) published a call
for the creation of 9 National Technological Clusters corresponding to different
high tech sectors, one of them is Life Science
For each sector only a single cluster has been created
Each Cluster presents 4 R&D projects
Total costs in between 10 and 12 millions of euro
A maximum of 8 proponents
Industrial partners covering at least the 50% of costs, with SME’s covering at
least the 15%
Public partners covering at least the 35% of costs
The MIUR supports the call with 368 millions of euro, 63 millions as a
contribution to the costs and 305 as subsidized credit. Moreover the MIUR
allocates additional 40 millions of euro of contribution for projects involving
Puglia, Calabria, Sicilia and Campania regions.
Perchè un Cluster
•
•
•
•
Nuove dinamiche di sviluppo verso le economie basate sulla conoscenza e
l’innovazione. Tra i fattori in grado di sostenere e promuovere la transizione
vi sono le “reti di conoscenza”.
In linea con iniziative a livello europeo, come la Strategia di Lisbona e la
“Europe 2020 Growth Strategy”, nella logica di un recupero di competitività
grazie allo sviluppo di un’economia basata sulla conoscenza e
sull’innovazione.
Una delle criticità che si intende superare con il Cluster è rappresentata dalla
frammentazione delle iniziative nell’ambito Scienze della Vita: senza
adeguata massa critica mancano effettive ricadute per l’intero sistema
Paese.
L’ambizione è quella di favorire l’aggregazione di risorse non solo a livello
regionale, ma anche tra i poli di riferimento nazionali e di entrare nelle grandi
reti di aggregazione europee, partecipando ai “mega cluster” transnazionali
che connettono i nodi specializzati esistenti in ciascun Paese (“Biotechnology
strategy and action plan” della Commissione Europea )
ALISEI - gli attori
• ALISEI raccoglie strutture
produttive e di ricerca, individuali
e aggregate, appartenenti a 12
Regioni
• In ALISEI sono rappresentate le
Associazioni di categoria:
Assobiomedica, Assobiotec,
Farmindustria e vi partecipa il
sistema pubblico della ricerca:
CNR, ENEA, ICE, IIT
• La governance di ALISEI è aperta,
per accogliere ulteriori componenti
scientifiche, industriali e
istituzionali coerenti con la sua
missione
ALISEI: Cluster Strategic positioning
•
Vision: To be a driving force in the economic growth of Italian regions in the
field of human health
•
Mission: To establish a national network of skills and capacities of
research, innovation and industrial development in the Life Science sector
with the aim of answering the social and economic challenges in the field of
human health
•
Timeline: At least 5 years
•
a)
b)
c)
Macrotrends:
Personalized approach and integration between therapy and diagnosis
Ageing and chronic diseases
Convergent technologies
The future
Geographical Area
International Level
Mega Cluster
2020
European Level
National level
Super Cluster
2018
Regional level
Cluster
Local level
2016
2011
Science Park
[-]
Virtual cluster integration
[++]
Relevance of geographical proximity
Fonte: TLS elaboration from Sternberg (2003)
TLS 2013
[++]
[-]
Thank you
Francesco Maria Senatore
Business Development
Communication & Projects
Tuscany Life Science Cluster & Foundation
Via Fiorentina, 1
53100 Siena ITALY
Tel.: +39 0577 231207
Mobile:+39 340 0917237
Fax: +39 0577 43444
[email protected]
www.toscanalifesciences.org
TLS 2013
Conclusions
• International visibility is key for R&D intensive and startup companies
• International presence is key for mature/expansion
companies
• Both types of SME can’t approach the market alone
• Science Parks and Cluster organizations play a very
important role in building up a real international network is
key and should go beyond the EU
TLS 2013
National Cluster ranking
41
41
TLS 2013
Post-Incubation Building
TLS 2013
International Benchmarking
TLS 2013
Biotech clusters in US
Cluster
Companies
Bay Area - San Francisco (California)
715
Maryland
350
San Diego (California)
240
Boston (Massachusetts)
220
Philadelphia (Pennsylvania)
135
From V. Chiesa – Bioforum, Milano 2007
FM Senatore Bio-Europe
46
Biotech clusters in EU
Cluster
Companies
Cambridge (UK)
422
Biovalley (France – Germany – Switzerland)
320
Munich (Germany)
150
Heidelberg (Germany)
121
Berlin – Brandeburg (Germany)
115
Medicon Valley (Sweden – Denmark)
110
Edinburgh Dundee Glasgow (UK)
75
Oxford (UK)
85
Evry – Ile de France (France)
54
From V. Chiesa – Bioforum, Milano 2007
FM Senatore Bio-Europe

similar documents